Welcome to our dedicated page for DECOY THERAPEUTICS news (Ticker: DCOY), a resource for investors and traders seeking the latest updates and insights on DECOY THERAPEUTICS stock.
Decoy Therapeutics Inc. develops preclinical peptide conjugate therapeutics built around Designable Multi-Antivirals, or D-MAVs, and its proprietary IMP3ACT platform. Company news centers on AI-enabled peptide design, rapid synthesis and manufacturing, respiratory-virus programs, and scientific presentations tied to pan-coronavirus and broad antiviral discovery efforts.
Recurring updates also include computational biology collaborations, non-dilutive program support, investor communications, capital-market actions, and Nasdaq listing-compliance matters. The company's public updates frame Decoy as a preclinical biotechnology issuer focused on respiratory viruses, with earlier company materials also referencing GI cancer pipeline work.
Decoy Therapeutics (Nasdaq:DCOY) nominated global biopharma executive Patricia Gauthier as a Class II director, with a shareholder vote planned at the 2026 Annual Meeting on July 14, 2026.
Gauthier brings leadership experience from Moderna and GSK across vaccines, commercialization and national health security partnerships.
Decoy Therapeutics (Nasdaq:DCOY) entered a strategic collaboration with hVIVO to advance its lead Designable Multi-Antiviral (D-MAV) candidate into Phase 1 and Phase 2a human proof-of-concept studies.
The partnership covers translational modeling, CMC, regulatory strategy, and documentation to support EMA, MHRA, FDA filings and future IND/CTA submissions for multi-virus respiratory antivirals discovered on the AI-enabled IMP³ACT platform.
Decoy Therapeutics (Nasdaq:DCOY), a clinical-stage biotech developing Designable Multi-Antivirals (D-MAVs™), appointed Brad L. Pentelute, Ph.D., MIT Professor of Chemistry and company co-founder, as Chair of its Scientific Advisory Board.
He will help guide Decoy's AI-enabled IMP3ACT™ peptide conjugate platform and multi-antiviral pipeline as programs advance toward clinical development.
Decoy Therapeutics (Nasdaq: DCOY) will present at two Boston peptide therapeutics conferences the week of April 27, 2026. Executives and advisors will discuss computational peptide design, peptide conjugate antivirals, and share new preclinical D-MAV data. The company highlighted a Quantori partnership and its IMP3ACT platform supporting pan-coronavirus and tripledemic programs.
Decoy Therapeutics (Nasdaq: DCOY) said it has accelerated execution across strategy, science and capital markets, advancing its AI-enabled IMP³ACT platform and D-MAV antiviral pipeline toward clinical development.
Key updates include an AI partnership with Quantori + Google Cloud (25–100x compute), a Gates Foundation global access commitment, non-dilutive funding, and a Phase 1 targeted in 2027.
Decoy Therapeutics (Nasdaq: DCOY) will host a Virtual Investor Closing Bell event on Thursday, April 9, 2026 at 4:00 PM ET featuring CEO Rick Pierce.
Mr. Pierce will provide a corporate overview and business outlook for 2026, take live investor questions, and a replay will be available two hours after the presentation for 90 days on the company investor events page.
Decoy Therapeutics (Nasdaq: DCOY) announced it regained compliance with Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement) effective March 31, 2026. The company is reported to be in compliance with all other continued listing requirements, but will be subject to a Mandatory Panel Monitor for one year from that date.
If the Listing Qualifications Staff finds renewed noncompliance during the one-year monitoring period, Nasdaq may issue a delisting determination letter and the company could request a hearing with the Nasdaq Hearings Panel.
Decoy Therapeutics (Nasdaq: DCOY) announced a strategic partnership with Quantori, supported by funding from Google Cloud, to build a Google Cloud-native, AI-driven peptide design and molecular simulation platform.
The production-grade, GPU-accelerated platform will integrate folding models, molecular dynamics, and Decoy's IMP³ACT engine, targeting a ~25- to 100-fold increase in computational throughput to accelerate antiviral peptide discovery.
Decoy Therapeutics (NASDAQ: DCOY) will effect a 1-for-12 reverse stock split at 5:00 p.m. ET on March 6, 2026, with split-adjusted trading beginning March 9, 2026 under CUSIP 79400X602.
The split reduces outstanding shares from ~6.38 million to ~532,000 and is intended to help Decoy regain compliance with Nasdaq's $1.00 minimum closing bid requirement. Outstanding options, warrants, and plan reserves will be adjusted and fractional shares will be paid in cash.
Decoy Therapeutics (NASDAQ: DCOY) announced on Feb 11, 2026 that it joined the Webull Corporate Connect Service platform to provide an additional communication channel for shareholders and investors. The company said the portal will distribute corporate news, earnings reports, product updates, presentations and notifications to improve transparency and engagement.